D
Inhibitor Therapeutics, Inc.
INTI
$0.06
$0.0120.00%
D
Sell
12/23/2024Upgraded
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D- from E+ on 12/23/2024 due to an increase in the volatility index.
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D- from E+ on 12/23/2024 due to an increase in the volatility index.
E
Sell
12/6/2024Downgrade
Inhibitor Therapeutics, Inc. (INTI) was downgraded to E+ from D- on 12/6/2024 due to a decline in the volatility index and total return index.
Inhibitor Therapeutics, Inc. (INTI) was downgraded to E+ from D- on 12/6/2024 due to a decline in the volatility index and total return index.
D
Sell
11/19/2024Upgraded
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D- from E+ on 11/19/2024 due to an increase in the volatility index and total return index.
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D- from E+ on 11/19/2024 due to an increase in the volatility index and total return index.
E
Sell
11/4/2024Downgrade
Inhibitor Therapeutics, Inc. (INTI) was downgraded to E+ from D- on 11/4/2024 due to a decline in the volatility index, total return index and growth index.
Inhibitor Therapeutics, Inc. (INTI) was downgraded to E+ from D- on 11/4/2024 due to a decline in the volatility index, total return index and growth index.
D
Sell
10/17/2024Upgraded
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D- from E+ on 10/17/2024 due to an increase in the total return index and volatility index.
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D- from E+ on 10/17/2024 due to an increase in the total return index and volatility index.
E
Sell
9/20/2024Downgrade
Inhibitor Therapeutics, Inc. (INTI) was downgraded to E+ from D- on 9/20/2024 due to a decline in the volatility index, total return index and valuation index.
Inhibitor Therapeutics, Inc. (INTI) was downgraded to E+ from D- on 9/20/2024 due to a decline in the volatility index, total return index and valuation index.
D
Sell
8/15/2024Upgraded
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D- from E+ on 8/15/2024 due to an increase in the volatility index, growth index and valuation index. Operating cash flow increased 49.65% from -$1.16M to -$583.1, earnings per share increased from -$0.004 to -$0.0029, and EBIT increased 24.48% from -$774.8 to -$585.1.
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D- from E+ on 8/15/2024 due to an increase in the volatility index, growth index and valuation index. Operating cash flow increased 49.65% from -$1.16M to -$583.1, earnings per share increased from -$0.004 to -$0.0029, and EBIT increased 24.48% from -$774.8 to -$585.1.
E
Sell
7/26/2024Downgrade
Inhibitor Therapeutics, Inc. (INTI) was downgraded to E+ from D- on 7/26/2024 due to a decline in the volatility index, solvency index and valuation index.
Inhibitor Therapeutics, Inc. (INTI) was downgraded to E+ from D- on 7/26/2024 due to a decline in the volatility index, solvency index and valuation index.
D
Sell
4/11/2024Downgrade
Inhibitor Therapeutics, Inc. (INTI) was downgraded to D- from C on 4/11/2024 due to a significant decline in the valuation index, efficiency index and growth index. Earnings per share declined from -$0.0039 to -$0.0092, net income declined 75.59% from -$664.8 to -$1.17M, and EBIT declined 67.65% from -$759.5 to -$1.27M.
Inhibitor Therapeutics, Inc. (INTI) was downgraded to D- from C on 4/11/2024 due to a significant decline in the valuation index, efficiency index and growth index. Earnings per share declined from -$0.0039 to -$0.0092, net income declined 75.59% from -$664.8 to -$1.17M, and EBIT declined 67.65% from -$759.5 to -$1.27M.
C
Hold
11/3/2023Upgraded
Inhibitor Therapeutics, Inc. (INTI) was upgraded to C from C- on 11/3/2023 due to a noticeable increase in the total return index and volatility index.
Inhibitor Therapeutics, Inc. (INTI) was upgraded to C from C- on 11/3/2023 due to a noticeable increase in the total return index and volatility index.
C
Hold
8/15/2023Upgraded
Inhibitor Therapeutics, Inc. (INTI) was upgraded to C- from D+ on 8/15/2023 due to a substantial increase in the growth index. Operating cash flow increased 9.86% from -$757.3 to -$682.6.
Inhibitor Therapeutics, Inc. (INTI) was upgraded to C- from D+ on 8/15/2023 due to a substantial increase in the growth index. Operating cash flow increased 9.86% from -$757.3 to -$682.6.
D
Sell
8/9/2023Upgraded
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D+ from D on 8/9/2023 due to an increase in the volatility index and total return index.
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D+ from D on 8/9/2023 due to an increase in the volatility index and total return index.
D
Sell
7/24/2023Downgrade
Inhibitor Therapeutics, Inc. (INTI) was downgraded to D from D+ on 7/24/2023 due to a decline in the volatility index and total return index.
Inhibitor Therapeutics, Inc. (INTI) was downgraded to D from D+ on 7/24/2023 due to a decline in the volatility index and total return index.
D
Sell
6/20/2023Upgraded
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D+ from D on 6/20/2023 due to an increase in the volatility index.
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D+ from D on 6/20/2023 due to an increase in the volatility index.
D
Sell
5/30/2023Downgrade
Inhibitor Therapeutics, Inc. (INTI) was downgraded to D from D+ on 5/30/2023 due to a substantial decline in the growth index, solvency index and total return index. Earnings per share declined from $0.0336 to -$0.0031, operating cash flow declined 106.36% from $11.9M to -$757.3, and EBIT declined 48.65% from -$423.6 to -$629.7.
Inhibitor Therapeutics, Inc. (INTI) was downgraded to D from D+ on 5/30/2023 due to a substantial decline in the growth index, solvency index and total return index. Earnings per share declined from $0.0336 to -$0.0031, operating cash flow declined 106.36% from $11.9M to -$757.3, and EBIT declined 48.65% from -$423.6 to -$629.7.
D
Sell
5/17/2023Downgrade
Inhibitor Therapeutics, Inc. (INTI) was downgraded to D+ from C- on 5/17/2023 due to a decline in the total return index and volatility index.
Inhibitor Therapeutics, Inc. (INTI) was downgraded to D+ from C- on 5/17/2023 due to a decline in the total return index and volatility index.
C
Hold
4/28/2023Upgraded
Inhibitor Therapeutics, Inc. (INTI) was upgraded to C- from D+ on 4/28/2023 due to an increase in the total return index and volatility index.
Inhibitor Therapeutics, Inc. (INTI) was upgraded to C- from D+ on 4/28/2023 due to an increase in the total return index and volatility index.
D
Sell
4/24/2023Upgraded
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D+ from E+ on 4/24/2023 due to a significant increase in the valuation index, solvency index and efficiency index. The quick ratio increased from 0.05 to 17.61, net income increased 16,007.85% from -$77.7 to $12.36M, and total capital increased 340.96% from -$3.61M to $8.71M.
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D+ from E+ on 4/24/2023 due to a significant increase in the valuation index, solvency index and efficiency index. The quick ratio increased from 0.05 to 17.61, net income increased 16,007.85% from -$77.7 to $12.36M, and total capital increased 340.96% from -$3.61M to $8.71M.
E
Sell
3/14/2023Downgrade
Inhibitor Therapeutics, Inc. (INTI) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index.
Inhibitor Therapeutics, Inc. (INTI) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index.
D
Sell
2/9/2023Upgraded
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D from E+ on 02/09/2023.
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
Inhibitor Therapeutics, Inc. (INTI) was downgraded to E+ from D on 2/8/2023 due to a noticeable decline in the total return index, volatility index and solvency index.
Inhibitor Therapeutics, Inc. (INTI) was downgraded to E+ from D on 2/8/2023 due to a noticeable decline in the total return index, volatility index and solvency index.
D
Sell
5/16/2022Upgraded
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D from E+ on 5/16/2022 due to an increase in the total return index.
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D from E+ on 5/16/2022 due to an increase in the total return index.
E
Sell
5/13/2022Downgrade
Inhibitor Therapeutics, Inc. (INTI) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
Inhibitor Therapeutics, Inc. (INTI) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
D
Sell
5/4/2022Upgraded
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D from E+ on 05/04/2022.
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
Inhibitor Therapeutics, Inc. (INTI) was downgraded to E+ from D on 05/01/2022.
Inhibitor Therapeutics, Inc. (INTI) was downgraded to E+ from D on 05/01/2022.
D
Sell
4/21/2022Upgraded
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D from E+ on 04/21/2022.
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
Inhibitor Therapeutics, Inc. (INTI) was downgraded to E+ from D on 4/20/2022 due to a decline in the solvency index. The quick ratio declined from 0.09 to 0.05.
Inhibitor Therapeutics, Inc. (INTI) was downgraded to E+ from D on 4/20/2022 due to a decline in the solvency index. The quick ratio declined from 0.09 to 0.05.
D
Sell
11/9/2021Upgraded
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D from E+ on 11/09/2021.
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Inhibitor Therapeutics, Inc. (INTI) was downgraded to E+ from D on 11/8/2021 due to a significant decline in the efficiency index, solvency index and valuation index. The quick ratio declined from 0.19 to 0.17, and total capital declined 1.27% from -$3.24M to -$3.28M.
Inhibitor Therapeutics, Inc. (INTI) was downgraded to E+ from D on 11/8/2021 due to a significant decline in the efficiency index, solvency index and valuation index. The quick ratio declined from 0.19 to 0.17, and total capital declined 1.27% from -$3.24M to -$3.28M.
D
Sell
4/29/2020Downgrade
Inhibitor Therapeutics, Inc. (INTI) was downgraded to D from D+ on 4/29/2020 due to a substantial decline in the solvency index, volatility index and total return index.
Inhibitor Therapeutics, Inc. (INTI) was downgraded to D from D+ on 4/29/2020 due to a substantial decline in the solvency index, volatility index and total return index.
D
Sell
3/31/2020Upgraded
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D+ from D on 3/31/2020 due to an increase in the volatility index, growth index and solvency index. EBIT increased 6.59% from -$682.9 to -$637.9.
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D+ from D on 3/31/2020 due to an increase in the volatility index, growth index and solvency index. EBIT increased 6.59% from -$682.9 to -$637.9.
D
Sell
3/30/2020Downgrade
Inhibitor Therapeutics, Inc. (INTI) was downgraded to D from D+ on 3/30/2020 due to a decline in the volatility index.
Inhibitor Therapeutics, Inc. (INTI) was downgraded to D from D+ on 3/30/2020 due to a decline in the volatility index.
D
Sell
3/2/2020Upgraded
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D+ from D on 3/2/2020 due to an increase in the volatility index and total return index.
Inhibitor Therapeutics, Inc. (INTI) was upgraded to D+ from D on 3/2/2020 due to an increase in the volatility index and total return index.
D
Sell
11/25/2019Downgrade
Inhibitor Therapeutics Inc. (INTI) was downgraded to D from D+ on 11/25/2019 due to a decline in the volatility index and total return index.
Inhibitor Therapeutics Inc. (INTI) was downgraded to D from D+ on 11/25/2019 due to a decline in the volatility index and total return index.
D
Sell
9/23/2019Upgraded
Inhibitor Therapeutics Inc. (INTI) was upgraded to D+ from D on 9/23/2019 due to an increase in the total return index and volatility index.
Inhibitor Therapeutics Inc. (INTI) was upgraded to D+ from D on 9/23/2019 due to an increase in the total return index and volatility index.
D
Sell
9/6/2019Downgrade
Inhibitor Therapeutics Inc. (INTI) was downgraded to D from D+ on 9/6/2019 due to a decline in the total return index, growth index and volatility index.
Inhibitor Therapeutics Inc. (INTI) was downgraded to D from D+ on 9/6/2019 due to a decline in the total return index, growth index and volatility index.
D
Sell
8/22/2019Upgraded
Inhibitor Therapeutics Inc. (INTI) was upgraded to D+ from D on 8/22/2019 due to a noticeable increase in the growth index, total return index and volatility index. Operating cash flow increased 38.09% from -$978 to -$605.5, earnings per share increased from -$0.0023 to -$0.0017, and EBIT increased 19.72% from -$791.6 to -$635.5.
Inhibitor Therapeutics Inc. (INTI) was upgraded to D+ from D on 8/22/2019 due to a noticeable increase in the growth index, total return index and volatility index. Operating cash flow increased 38.09% from -$978 to -$605.5, earnings per share increased from -$0.0023 to -$0.0017, and EBIT increased 19.72% from -$791.6 to -$635.5.
D
Sell
5/15/2019Upgraded
HedgePath Pharmaceuticals, Inc. (HPPI) was upgraded to D from D- on 5/15/2019 due to a significant increase in the efficiency index and valuation index. Net income increased 40.71% from -$1.33M to -$786.3.
HedgePath Pharmaceuticals, Inc. (HPPI) was upgraded to D from D- on 5/15/2019 due to a significant increase in the efficiency index and valuation index. Net income increased 40.71% from -$1.33M to -$786.3.
D
Sell
3/12/2019Upgraded
HedgePath Pharmaceuticals, Inc. (HPPI) was upgraded to D- from E+ on 3/12/2019 due to a noticeable increase in the efficiency index and solvency index.
HedgePath Pharmaceuticals, Inc. (HPPI) was upgraded to D- from E+ on 3/12/2019 due to a noticeable increase in the efficiency index and solvency index.
E
Sell
1/17/2019Downgrade
HedgePath Pharmaceuticals, Inc. (HPPI) was downgraded to E+ from D- on 1/17/2019 due to a large decline in the total return index, growth index and volatility index. EBIT declined 32.91% from -$884.4 to -$1.18M, earnings per share declined from -$0.0025 to -$0.0033, and operating cash flow declined 20.95% from -$789.5 to -$954.9.
HedgePath Pharmaceuticals, Inc. (HPPI) was downgraded to E+ from D- on 1/17/2019 due to a large decline in the total return index, growth index and volatility index. EBIT declined 32.91% from -$884.4 to -$1.18M, earnings per share declined from -$0.0025 to -$0.0033, and operating cash flow declined 20.95% from -$789.5 to -$954.9.
D
Sell
7/24/2018Downgrade
HedgePath Pharmaceuticals, Inc. (HPPI) was downgraded to D- from D on 7/24/2018 due to a decline in the efficiency index, solvency index and volatility index. Total capital declined 53.03% from $1.54M to $722.6, and the quick ratio declined from 3.57 to 1.72.
HedgePath Pharmaceuticals, Inc. (HPPI) was downgraded to D- from D on 7/24/2018 due to a decline in the efficiency index, solvency index and volatility index. Total capital declined 53.03% from $1.54M to $722.6, and the quick ratio declined from 3.57 to 1.72.
D
Sell
2/16/2018Upgraded
HedgePath Pharmaceuticals, Inc. (HPPI) was upgraded to D from D- on 2/16/2018 due to an increase in the efficiency index and growth index. Operating cash flow increased 28.15% from -$756 to -$543.2.
HedgePath Pharmaceuticals, Inc. (HPPI) was upgraded to D from D- on 2/16/2018 due to an increase in the efficiency index and growth index. Operating cash flow increased 28.15% from -$756 to -$543.2.
D
Sell
2/9/2018Upgraded
HedgePath Pharmaceuticals, Inc. (HPPI) was upgraded to D- from E+ on 2/9/2018 due to an increase in the valuation index, total return index and volatility index.
HedgePath Pharmaceuticals, Inc. (HPPI) was upgraded to D- from E+ on 2/9/2018 due to an increase in the valuation index, total return index and volatility index.
E
Sell
1/25/2018Downgrade
HedgePath Pharmaceuticals, Inc. (HPPI) was downgraded to E+ from D- on 1/25/2018 due to a decline in the valuation index.
HedgePath Pharmaceuticals, Inc. (HPPI) was downgraded to E+ from D- on 1/25/2018 due to a decline in the valuation index.
D
Sell
11/27/2017Upgraded
HedgePath Pharmaceuticals, Inc. (HPPI) was upgraded to D- from E+ on 11/27/2017 due to an increase in the valuation index.
HedgePath Pharmaceuticals, Inc. (HPPI) was upgraded to D- from E+ on 11/27/2017 due to an increase in the valuation index.
E
Sell
11/1/2017Downgrade
HedgePath Pharmaceuticals, Inc. (HPPI) was downgraded to E+ from D- on 11/1/2017 due to a significant decline in the total return index, efficiency index and solvency index. Total capital declined 38.62% from $1.72M to $1.06M, and the quick ratio declined from 4.84 to 3.52.
HedgePath Pharmaceuticals, Inc. (HPPI) was downgraded to E+ from D- on 11/1/2017 due to a significant decline in the total return index, efficiency index and solvency index. Total capital declined 38.62% from $1.72M to $1.06M, and the quick ratio declined from 4.84 to 3.52.
D
Sell
8/1/2017Downgrade
HedgePath Pharmaceuticals, Inc. (HPPI) was downgraded to D- from D on 8/1/2017 due to a major decline in the total return index, efficiency index and solvency index. Total capital declined 27.64% from $2.38M to $1.72M, and the quick ratio declined from 5.91 to 4.84.
HedgePath Pharmaceuticals, Inc. (HPPI) was downgraded to D- from D on 8/1/2017 due to a major decline in the total return index, efficiency index and solvency index. Total capital declined 27.64% from $2.38M to $1.72M, and the quick ratio declined from 5.91 to 4.84.
D
Sell
10/6/2016Downgrade
HedgePath Pharmaceuticals, Inc. (HPPI) was downgraded to D from D+ on 10/6/2016 due to a decline in the valuation index.
HedgePath Pharmaceuticals, Inc. (HPPI) was downgraded to D from D+ on 10/6/2016 due to a decline in the valuation index.
D
Sell
9/21/2016Upgraded
HedgePath Pharmaceuticals, Inc. (HPPI) was upgraded to D+ from D on 9/21/2016 due to an increase in the valuation index and total return index.
HedgePath Pharmaceuticals, Inc. (HPPI) was upgraded to D+ from D on 9/21/2016 due to an increase in the valuation index and total return index.
D
Sell
8/19/2016Downgrade
HedgePath Pharmaceuticals, Inc. (HPPI) was downgraded to D from D+ on 8/19/2016 due to a decline in the valuation index and volatility index.
HedgePath Pharmaceuticals, Inc. (HPPI) was downgraded to D from D+ on 8/19/2016 due to a decline in the valuation index and volatility index.
D
Sell
8/12/2016Downgrade
HedgePath Pharmaceuticals, Inc. (HPPI) was downgraded to D+ from C- on 8/12/2016 due to a significant decline in the efficiency index, valuation index and growth index. Operating cash flow declined 108.14% from -$482.8 to -$1M, EBIT declined 11.35% from -$1.19M to -$1.33M, and net income declined 11.26% from -$1.19M to -$1.33M.
HedgePath Pharmaceuticals, Inc. (HPPI) was downgraded to D+ from C- on 8/12/2016 due to a significant decline in the efficiency index, valuation index and growth index. Operating cash flow declined 108.14% from -$482.8 to -$1M, EBIT declined 11.35% from -$1.19M to -$1.33M, and net income declined 11.26% from -$1.19M to -$1.33M.
C
Hold
5/13/2016Upgraded
HedgePath Pharmaceuticals, Inc. (HPPI) was upgraded to C- from D on 5/13/2016 due to a significant increase in the efficiency index and valuation index.
HedgePath Pharmaceuticals, Inc. (HPPI) was upgraded to C- from D on 5/13/2016 due to a significant increase in the efficiency index and valuation index.
D
Sell
2/4/2016Downgrade
HedgePath Pharmaceuticals, Inc. (HPPI) was downgraded to D from D+ on 2/4/2016 due to a significant decline in the total return index, solvency index and valuation index. The quick ratio declined from 2.3 to 1.3.
HedgePath Pharmaceuticals, Inc. (HPPI) was downgraded to D from D+ on 2/4/2016 due to a significant decline in the total return index, solvency index and valuation index. The quick ratio declined from 2.3 to 1.3.
D
Sell
12/3/2015Downgrade
HedgePath Pharmaceuticals, Inc. (HPPI) was downgraded to D+ from C- on 12/3/2015 due to a decline in the total return index.
HedgePath Pharmaceuticals, Inc. (HPPI) was downgraded to D+ from C- on 12/3/2015 due to a decline in the total return index.
C
Hold
11/18/2015Upgraded
HedgePath Pharmaceuticals, Inc. (HPPI) was upgraded to C- from D on 11/18/2015 due to a substantial increase in the total return index.
HedgePath Pharmaceuticals, Inc. (HPPI) was upgraded to C- from D on 11/18/2015 due to a substantial increase in the total return index.
D
Sell
11/5/2015Downgrade
HedgePath Pharmaceuticals, Inc. (HPPI) was downgraded to D from D+ on 11/5/2015 due to a large decline in the volatility index, valuation index and efficiency index. Total capital declined 43.2% from $1.78M to $1.01M.
HedgePath Pharmaceuticals, Inc. (HPPI) was downgraded to D from D+ on 11/5/2015 due to a large decline in the volatility index, valuation index and efficiency index. Total capital declined 43.2% from $1.78M to $1.01M.
D
Sell
5/14/2015Upgraded
HedgePath Pharmaceuticals, Inc. (HPPI) was upgraded to D+ from D on 5/14/2015 due to a major increase in the volatility index, valuation index and efficiency index. Net income increased 2.74% from -$898.1 to -$922.7.
HedgePath Pharmaceuticals, Inc. (HPPI) was upgraded to D+ from D on 5/14/2015 due to a major increase in the volatility index, valuation index and efficiency index. Net income increased 2.74% from -$898.1 to -$922.7.
D
Sell
2/13/2015Downgrade
HedgePath Pharmaceuticals, Inc. (HPPI) was downgraded to D from D+ on 2/13/2015 due to a noticeable decline in the valuation index, efficiency index and volatility index.
HedgePath Pharmaceuticals, Inc. (HPPI) was downgraded to D from D+ on 2/13/2015 due to a noticeable decline in the valuation index, efficiency index and volatility index.
D
Sell
8/15/2014Downgrade
HedgePath Pharmaceuticals, Inc. (HPPI) was downgraded to D+ from C- on 8/15/2014 due to a significant decline in the efficiency index, total return index and solvency index. Total capital declined 87.58% from -$409.7 to -$50.9, and debt to equity increased from -0.57 to -0.67.
HedgePath Pharmaceuticals, Inc. (HPPI) was downgraded to D+ from C- on 8/15/2014 due to a significant decline in the efficiency index, total return index and solvency index. Total capital declined 87.58% from -$409.7 to -$50.9, and debt to equity increased from -0.57 to -0.67.
OTC PK
04/01/2025 1:04PM Eastern
Quotes delayed
